Effectiveness of BA.1-and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
Arashiro, T; Arima, Y; Kuramochi, J; Muraoka, H; Sato, A; Chubachi, K; Yanai, A; Arioka, H; Uehara, Y; Ihara, G; Kato, Y; Yanagisawa, N; Ueda, A; Kato, H; Oka, H; Nishida, Y; Nidaira, Y; Asami, T; Jinta, T; Nakamura, A; Oba, K; Taniyama, D; Yamamoto, K; Tanaka, K; Ueshima, K; Fuwa, T; Stucky, A; Suzuki, T; Smith, C; Hibberd, M; Ariyoshi, K; Suzuki, M
Arashiro, T (通讯作者)，Natl Inst Infect Dis, Ctr Surveillance Immunizat & Epidemiol Res, Tokyo, Japan.;Arashiro, T (通讯作者)，Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan.;Arashiro, T (通讯作者)，London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England.;Arashiro, T (通讯作者)，Nagasaki Univ, Sch Trop Med & Global Hlth, Nagasaki, Japan.
OPEN FORUM INFECTIOUS DISEASES, 2023; 10 (6):
